Literature DB >> 8084493

Allogeneic grafts of fetal dopamine neurons: behavioral indices of immunological interactions.

J L Hudson1, A Hoffman, I Strömberg, B J Hoffer, J W Moorhead.   

Abstract

Fetal central nervous system transplants to the adult brain have been utilized to understand brain connectivity and as replacement therapy in Parkinson's disease (PD). Here we use fetal brain allografting in the rat unilaterally depleted of dopamine, a unilateral model of PD, and apomorphine-induced rotations as an index of graft functional status while peripherally manipulating the host's alloimmune status. This system allows the investigator to examine, dynamically, host-allograft interactions in the brain under differing states of alloimmunoreactivity without the need to biopsy or sacrifice the animal. In addition to this novel application, we established that brain allografts are differentially susceptible to immunologic attack depending upon the graft's duration of residence in the host brain. Increasing residence time increases graft 'rejectability' to peripheral allosensitization. Passive immunization also sensitizes the host to subsequent graft rejection. Lastly, simple host alloimmunocompetence is necessary but not sufficient to cause fetal graft 'rejection', defined as a return of apomorphine-induced rotations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8084493     DOI: 10.1016/0304-3940(94)90597-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

Review 1.  Cell therapy in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  NeuroRx       Date:  2004-10

2.  Understanding and prevention of "therapy-" induced dyskinesias.

Authors:  Iciar Aviles-Olmos; Zinovia Kefalopoulou; Thomas Foltynie
Journal:  Parkinsons Dis       Date:  2012-05-23

3.  Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate.

Authors:  Asuka Morizane; Daisuke Doi; Tetsuhiro Kikuchi; Keisuke Okita; Akitsu Hotta; Toshiyuki Kawasaki; Takuya Hayashi; Hirotaka Onoe; Takashi Shiina; Shinya Yamanaka; Jun Takahashi
Journal:  Stem Cell Reports       Date:  2013-09-26       Impact factor: 7.765

Review 4.  The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson's disease.

Authors:  Shamma Qarin; Sarah K Howlett; Joanne L Jones; Roger A Barker
Journal:  Neuronal Signal       Date:  2021-09-13

5.  L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease.

Authors:  Osama F Elabi; Jeffrey S Davies; Emma L Lane
Journal:  Int J Mol Sci       Date:  2021-11-16       Impact factor: 5.923

6.  Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease.

Authors:  Anna Tamburrino; Madeline J Churchill; Oi W Wan; Yolanda Colino-Sanguino; Rossana Ippolito; Sofie Bergstrand; Daniel A Wolf; Niculin J Herz; Michelle D Sconce; Anders Björklund; Charles K Meshul; Mickael Decressac
Journal:  Acta Neuropathol Commun       Date:  2015-12-14       Impact factor: 7.801

Review 7.  Foetal Cell Transplantation for Parkinson's Disease: Focus on Graft-Induced Dyskinesia.

Authors:  Elisabetta Tronci; Camino Fidalgo; Manolo Carta
Journal:  Parkinsons Dis       Date:  2015-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.